This content is from: Features

How to ensure the safety of biosimilars in India

Archana Shanker and Devinder Singh Rawat of Anand & Anand discuss the rise and regulation of biosimilar biologics in the Indian pharmaceutical market

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial